Emergent BioSolutions | L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 44.6M 4.38M 2025-09
Akebia Therapeutics USD 6.11M 28.92M 2025-03
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -8.12M 5.34M 2025-09
ANI Pharmaceuticals USD 49.52M 39M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Coherus Biosciences USD -47.4M 14.9M 2025-03
Exact Sciences USD -17.76M 17.7M 2025-09
Exelixis USD 252.69M 275K 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Heron Therapeutics USD -4.85M 4.39M 2024-09
Ionis Pharmaceuticals USD -129M 253M 2025-09
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Lexicon Pharmaceuticals USD -53.43M 5.03M 2024-06
Lonza CHF 624M 197M 2024-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Myriad Genetics USD 6.2M 2.1M 2024-12
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Pacira USD -1.93M 10.63M 2025-06
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -23.07M 47.98M 2025-09
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -194.05M 347.69M 2025-09
United Therapeutics USD 438M 29.6M 2025-09
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Xoma USD 15.98M 24.58M 2024-06


Emergent BioSolutions L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.